Clinical trial
Safety, Tolerance and Pharmacokinetics of Anidulafungin in Immunocompromised…
NCT00056381 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00056381 |
|---|---|
| Title | Safety, Tolerance and Pharmacokinetics of Anidulafungin in Immunocompromised Children Ages 2-17 |
| Official title | Phase I/II Study of the Safety, Tolerance and Pharmacokinetics of Anidulafungin in Immunocompromised Children With Fever and Neutropenia |
| Lead sponsor | Pfizer, Industry |
| Collaborators | Vicuron Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Neutropenia |
| Intervention type | Drug |
| Interventions | Anidulafungin |
| Enrollment | 25 |
| Start date | Jul 1, 2003 |
| Completion | Jun 1, 2004 |
| First posted | Mar 12, 2003 |
| Last update posted | Oct 21, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: